Hormone Receptor-Positive Breast Cancer

Focusing on estrogen and progesterone receptor-positive (HR+) breast cancer, this session explores endocrine therapy developments and resistance mechanisms. Discussions will cover selective estrogen receptor degraders (SERDs), aromatase inhibitors, and the integration of CDK4/6 inhibitors. Attendees will learn about personalized approaches and long-term treatment strategies aimed at disease control and quality-of-life improvement for HR+ patients.

    Related Conference of Hormone Receptor-Positive Breast Cancer

    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 20-21, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    December 08-09, 2025

    13th Euro Breast Cancer and Therapeutics

    Aix-en-Provence, France
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Hormone Receptor-Positive Breast Cancer Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in